
T-DXd Plus Pertuzumab Could Disrupt First-Line SOC in HER2+ Metastatic Breast Cancer
The significant progression-free survival (PFS) benefit observed with fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) in the first-line setting for HER2-positive metastatic breast cancer marks the first time in …